Ruby Cheema

Currently a Senior Director, Alliance Management at 4D Molecular Therapeutics, Ruby has worked in biotechnology her entire career. Her current role is to manage and optimize the value of the alliance portfolio consisting of strategic industry and academic partnerships/collaborations to achieve defined strategic goals while supporting business development on strategic discussions and contract negotiations for potential new agreements.

Prior to 4DMT, Ruby was a Director of Program, Alliance, and Portfolio Management at Unity Biotechnology. Her role included managing programs from drug screening in discovery to managing development programs, alliance, and portfolio management. She began her Project Management journey at Genentech almost 15 years ago. In the past 15 years, Ruby has led the Perjeta™ (metastatic breast cancer) team as a project manager from PhIII to Launch and Tecentriq™ (break-through therapy oncology) team from Ph0 to PhII. She managed multiple teams in various therapeutic areas including oncology, ophthalmology, Osteoarthritis, lung disease etc. She has held various roles of increasing responsibility at Genentech/Roche in multiple functions where she influenced global strategies including Roche Drug Substance Network Roadmap, project/portfolio management, and global filings. Prior to Genentech, Ruby was an Associate Scientist in process development and part of the team for Flumist™ through launch including HA inspections etc., in R&D and clinical research for One Touch™ Glucose Meter strips.

Ruby has a great passion for science, strategy, and collaboration via project management. She is keen to take this combination to new horizons. She has served as BioPharmaPM Network Co-chair since 2017 and has been involved with the organization in a leadership role since 2015 as Director of Membership.